Published in Blood Weekly, June 15th, 2000
Victor L. Serebruany, of the Sinai Center for Thrombosis Research in Baltimore, Maryland, and colleagues investigated why patients who have clinical depression are less likely to survive after acute coronary events. They studied how sertraline, a serotonin reuptake inhibitor, and its primary metabolite in the liver, N-desmethylsertraline (NDMS), influence human platelets in vitro.
Serebruany et al. presented their study at 49th Annual Scientific Session of the American College of Cardiology, held in Anaheim, California. Their study was titled "Platelet Inhibition...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.